Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair (Q30656233)

1 July 2019

review article

0 references

title

Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair (English)

1 reference

1 July 2019

0 references

5

0 references

Marcus W Koch

object named as

Marcus W Koch

3

0 references

Scott B. Patten

object named as

Scott B Patten

6

0 references

author name string

Simon Zhornitsky

1

1 reference

1 July 2019

Voon Wee Yong

2

1 reference

1 July 2019

Aaron Mackie

4

1 reference

1 July 2019

Luanne M Metz

7

1 reference

1 July 2019

publication date

22 July 2013

1 reference

1 July 2019

CNS Neuroscience & Therapeutics

published in

1 reference

1 July 2019

volume

19

1 reference

1 July 2019

issue

10

1 reference

1 July 2019

page(s)

737-744

1 reference

1 July 2019

Will the real multiple sclerosis please stand up?

cites work

1 reference

Prolactin in multiple sclerosis.

21 January 2018

1 reference

Neuroprotection and repair in multiple sclerosis

21 January 2018

1 reference

Approaches to neuroprotective strategies in multiple sclerosis

21 January 2018

1 reference

Astrocytes as potential targets to suppress inflammatory demyelinating lesions in multiple sclerosis

21 January 2018

1 reference

In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis

21 January 2018

1 reference

Comparison of myelin, axon, lipid, and immunopathology in the central nervous system of differentially myelin-compromised mutant mice: a morphological and biochemical study

21 January 2018

1 reference

N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity

21 January 2018

1 reference

Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes.

21 January 2018

1 reference

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials

21 January 2018

1 reference

An open-label study of quetiapine in the treatment of fibromyalgia.

21 January 2018

1 reference

Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial.

21 January 2018

1 reference

An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine

21 January 2018

1 reference

Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse.

21 January 2018

1 reference

Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics.

21 January 2018

1 reference

Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice.

21 January 2018

1 reference

Differential effects of antipsychotics on the development of rat oligodendrocyte precursor cells exposed to cuprizone

21 January 2018

1 reference

Quetiapine enhances oligodendrocyte regeneration and myelin repair after cuprizone-induced demyelination.

21 January 2018

1 reference

Quetiapine prevents oligodendrocyte and myelin loss and promotes maturation of oligodendrocyte progenitors in the hippocampus of global cerebral ischemia mice.

21 January 2018

1 reference

Quetiapine, an atypical antipsychotic, is protective against autoimmune-mediated demyelination by inhibiting effector T cell proliferation

21 January 2018

1 reference

The cuprizone animal model: new insights into an old story

21 January 2018

1 reference

The life, death, and replacement of oligodendrocytes in the adult CNS.

21 January 2018

1 reference

Quetiapine attenuates spatial memory impairment and hippocampal neurodegeneration induced by bilateral common carotid artery occlusion in mice.

21 January 2018

1 reference

Quetiapine attenuates the depressive and anxiolytic-like behavioural changes induced by global cerebral ischemia in mice.

21 January 2018

1 reference

Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters

21 January 2018

1 reference

Increased carbonylation, protein aggregation and apoptosis in the spinal cord of mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+‐induced apoptosis

21 January 2018

1 reference

Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal

21 January 2018

1 reference

Differential effects of classical and atypical antipsychotic drugs on rotenone-induced neurotoxicity in PC12 cells.

21 January 2018

1 reference

Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis

21 January 2018

1 reference

Demonstration of an anti-oxidative stress mechanism of quetiapine: implications for the treatment of Alzheimer's disease.

21 January 2018

1 reference

Effect of atypical antipsychotics on antioxidant enzyme activities in human erythrocytes (in vitro study).

21 January 2018

1 reference

Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro

21 January 2018

1 reference

Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics

21 January 2018

1 reference

Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models

21 January 2018

1 reference

Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion

21 January 2018

1 reference

Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis

21 January 2018

1 reference

Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination

21 January 2018

1 reference

Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate.

21 January 2018

1 reference

Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus

21 January 2018

1 reference

Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats.

21 January 2018

1 reference

Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801.

21 January 2018

1 reference

Effects of antipsychotic drugs on the expression of synaptic proteins and dendritic outgrowth in hippocampal neuronal cultures

21 January 2018

1 reference

N-desalkylquetiapine activates ERK1/2 to induce GDNF release in C6 glioma cells: a putative cellular mechanism for quetiapine as antidepressant

21 January 2018

1 reference

Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats

21 January 2018

1 reference

Therapeutic potential of fluoxetine in neurological disorders

21 January 2018

1 reference

The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma.

21 January 2018

1 reference

Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse.

21 January 2018

1 reference

Impact of antipsychotics on cytokine production in-vitro.

21 January 2018

1 reference

Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders

21 January 2018

1 reference

The soluble interleukin-2 receptor: biology, function, and clinical application

21 January 2018

1 reference

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse

21 January 2018

1 reference

Suicide and multiple sclerosis: an epidemiological investigation

21 January 2018

1 reference

Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

Prevalence of sleep problems in individuals with multiple sclerosis

21 January 2018

1 reference

Sleep disorders and fatigue in multiple sclerosis: evidence for association and interaction

21 January 2018

1 reference

Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects

21 January 2018

1 reference

Quetiapine for insomnia in Parkinson disease: results from an open-label trial

21 January 2018

1 reference

Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis

21 January 2018

1 reference

Effectiveness of duloxetine for the treatment of chronic nonorganic orofacial pain

21 January 2018

1 reference

Antipsychotics for acute and chronic pain in adults

21 January 2018

1 reference

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

21 January 2018

1 reference

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

21 January 2018

1 reference

Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.

21 January 2018

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy

21 January 2018

1 reference

Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine

21 January 2018

1 reference

T2 MRI texture analysis is a sensitive measure of tissue injury and recovery resulting from acute inflammatory lesions in multiple sclerosis.

21 January 2018

1 reference

Psychotic disorders in MS: Population-based evidence of an association

21 January 2018

1 reference

Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population

21 January 2018

1 reference

12 December 2020

Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells.

1 reference

12 December 2020

Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study

1 reference

12 December 2020

Quetiapine for primary insomnia: a double blind, randomized controlled trial

1 reference

12 December 2020

Measuring myelin repair and axonal loss with diffusion tensor imaging.

1 reference

12 December 2020

1 reference

12 December 2020

Animal models of multiple sclerosis: the good, the bad and the bottom line

1 reference

12 December 2020

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

1 reference

12 December 2020

Early onset of action and sleep-improving effect are crucial in decreasing suicide risk: the role of quetiapine XR in the treatment of unipolar and bipolar depression

1 reference

12 December 2020

Amitriptyline for neuropathic pain and fibromyalgia in adults

1 reference

12 December 2020

Neurotransmitter signaling in the pathophysiology of microglia

1 reference

12 December 2020

Mood disorder and multiple sclerosis

1 reference

12 December 2020

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1111/CNS.12154

1 reference

1 July 2019

PMCID

6493439

1 reference

1 July 2019

PubMed ID

23870612

1 reference

1 July 2019